Abbonarsi

Upper urinary tract tumors with nontransitional histology: A single-center experience - 16/08/11

Doi : 10.1016/j.urology.2005.09.010 
J. Erik Busby a, Gordon A. Brown a, Pheroze Tamboli b, Ashish M. Kamat a, Colin P.N. Dinney a, H. Barton Grossman a, Surena F. Matin a,
a Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA 
b Department of Pathology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA 

Reprint requests: Surena F. Matin, M.D., Department of Urology, University of Texas M. D. Anderson Cancer Center, Unit 1373, 1515 Holcombe Boulevard, Houston, TX 77030-4009.

Abstract

Objectives

To review our experience with patients with upper urinary tract tumors of nonurothelial origin. Upper urinary tract tumors of nonurothelial origin are uncommon entities. To our knowledge, no series of patients with these neoplasms has been published in the past decade.

Methods

We reviewed the records at the University of Texas M. D. Anderson Cancer Center from 1990 to 2004 to identify patients with primary nonurothelial tumors of the upper urinary tract. We reviewed the patient records to collect data on tumor subtype, treatment, recurrence, and survival.

Results

Sixteen patients (1.9% of our database of patients with upper urinary tract tumors) were identified; 12 had squamous cell carcinoma, 2 had adenocarcinoma, 1 had sarcomatoid carcinoma, and 1 had small cell carcinoma. The tumors were located in the renal pelvis in 10 and the ureter in 6. Of the 16 patients, 15 had been treated with nephrectomy or nephrouterectomy and 1 with chemotherapy and radiotherapy. Fifteen of the tumors were pathologic Stage T3 or worse. Ten patients received adjuvant chemotherapy. Of the 16 patients, 9 died (1 of unknown causes), 4 were alive without disease, 2 were alive with disease, and 1 was alive at last follow-up with the disease status unknown. The median follow-up was 30.1 months, the median overall survival time was 11.3 months, and 1-year survival rate was 46%. The median recurrence-free survival time and 1-year recurrence-free survival rate were 5.8 months and 38%, respectively.

Conclusions

Primary nonurothelial carcinomas of the renal pelvis and ureter are rare. Our analysis suggests a poor prognosis for most patients with these pathologic types, probably resulting from the advanced stage at diagnosis and poor responses to systemic therapy.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 This study was supported by the M. D. Anderson Bladder SPORE grant (CA91846) and a Department of Urology T32 Training Grant (CA79449).


© 2006  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 67 - N° 3

P. 518-523 - marzo 2006 Ritorno al numero
Articolo precedente Articolo precedente
  • Percutaneous nephrolithotomy for ectopic kidneys: Over, around, or through
  • Brian R. Matlaga, Samuel C. Kim, Stephanie L. Watkins, Ramsay L. Kuo, Larry C. Munch, James E. Lingeman
| Articolo seguente Articolo seguente
  • Effect of tension-free vaginal tape operation on urethral closure function
  • Dieter Koelle, Johannes Windisch, Daniela Doerfler, Christian Marth, Stephan Kropshofer

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.